

8. HEIMILDASKRÁ

- Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osińska, B., Herholz, H., Wendykowska, K. o.fl. (2010). Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Services Research*, 10(153). doi:10.1186/1472-6963-10-153
- Almarsdóttir, A. B. (2005). Eigindlegar aðferðir. *Læknablaðið*, 91(2). Sótt af <http://www.laeknabladid.is/2005/02/nr/1974>
- Almarsdóttir, A. B. og Traulsen, J. (2005a). Cost-containment as part of pharmaceutical policy. *Pharmacy World and Science*, 27(3), 144-148. doi:10.1007/s11096-005-6953-6
- Almarsdóttir, A. B. og Traulsen, J. (2005b). Rational use of medicines – an important issue in pharmaceutical policy. *Pharmacy World and Science*, 27(2), 76-80. doi:10.1007/s11096-005-3303-7
- Barbieri, M., Drummond, M., Wilke, R., Chancellor, J., Jolain, B. og Towse, A. (2005). Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability. *Value in Health*, 8(1), 10-23.
- Boston Consulting Group. (2011). *Health care system reform and short term savings opportunities. Iceland health care system project [skýrsla]*. Sótt af http://www.velferdarraduneyti.is/media/ritogskyrslur2011/Iceland_HCS-Final_report-_Long_version.pdf
- Brekke, K. R., Holmås, T. H., Straume, O. R. (2011). *SNF report no. 11/11. Comparing Pharmaceutical Prices in Europe. A comparison of prescription drug prices in Norway with nine Western European countries*. Sótt af <http://www.nhh.no/Files/Filer/institutter/sam/cv/papers/Report2011-final.pdf>
- Brekke, K. R., Dalen, D. M. og Holmås, T.H. (2013). *Diffusion of pharmaceuticals: Cross-country evidence of anti-TNF drugs [umræðugrein]*. Sótt af <http://www.nhh.no/Files/Filer/institutter/sam/Discussion%20papers/2013/07.pdf>

- Böðvarsson, S. (2010). Hlutverk lækna í hagræðingu innan heilbrigðiskerfisins. [ritstjórnargrein]. *Læknablaðið*, 96(4). Sótt af <http://www.laeknabladid.is/tolublod/2010/04/nr/3804>
- Danmarks Apotekerforening. (2013). Udgifterne til apoteksmedicin faldt med 4 procent i 2012. Sótt af http://www.apotekerforeningen.dk/%20~/media/Apotekerforeningen/analyseroekonomi/23012013_laegemidler_i_dk_2012.ashx
- Drummond, M. og McGuire, A. (2005). *Economic evaluation in health care: Merging theory with practice*. Oxford: Oxford University Press.
- Esterberg, K. G. (2002). *Qualitative methods in social research*. Boston: McGraw Hill.
- EurLex. (1989). Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Sótt af <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:EN:HTML>
- European Commission. (e. d.). Transparent value framework. Sótt af http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/orphans_framework_en.pdf
- Ferrario, A. og Kanavos, P. (ritstj). (2013). *Managed entry agreements for pharmaceuticals: the European experience*. Sótt af http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf
- Festøy, H., Yu, L. M., Aanes, T., Ognøy, A. H., Gregersen, T., Schmickl, B. o.fl. (2011). PHIS pharma profile – Norway 2011 [1. útgáfa]. Sótt af: <http://www.legemiddelverket.no/English/the-norwegian-health-care-system-and-pharmaceutical-system/Documents/PHIS%20Pharma%20profile.pdf>
- Garattini, S., Bertele', V., Godman, B., Haycox, A., Wettermark, B. og Gustafsson, L. (2008). Enhancing the rational use of new medicines across European health care systems. *European Journal of Clinical Pharmacology*, 64(12), 1137-1138. doi:10.1007/s00228-008-0537-z

- Garrison Jr., L. P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J. og Mohr, P. E. (2013). Performance-based risk-sharing arrangements - Good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. *Value in Health*, 16(5), 703-719. doi: 10.1016/j.jval.2013.04.011
- Godman, B., Paterson, K., Malmström, R. E., Selke, G., Fagot, J.-P. og Mrak, J. (2012). Improving the managed entry of new medicines: Sharing experiences across Europe. *Expert Review of Pharmacoeconomics & Outcomes Research*, 12(4), 439-441. doi:10.1586/erp.12.44
- Golan, D. E., Tashjian, A. H. Jr., Armstrong, E. J., Armstrong, A. W. (2008). *Principles of pharmacology. The pathophysiologic basis of drug therapy* (2. útgáfa). Philadelphia: Lippincott Williams & Wilkins.
- Gröndal, G. og Björnsson, E. S. (2013). Lyfjamál í brennidepli [ritstjórnargrein]. *Læknablaðið*, 99(5). Sótt af <http://www.laeknabladid.is/tolublod/2013/05/nr/4848>
- Guion, L. A., Diehl, D. C. og McDonald, D. (2009). *Triangulation: Establishing the validity of qualitative studies*. Sótt af <http://edis.ifas.ufl.edu/fy394>
- Gylfadóttir, G. I. og Haraldsson, H. G. (2010). Breytingar á greiðslupáttöku lyfja – hvað hefur áunnist? *Læknablaðið*, 96(7/8). Sótt af <http://www.laeknabladid.is/media/tolublod/1493/PDF/u10.pdf>
- Hancock, D. R. og Algozzine, B. (2011). Doing case study research. A practical guide for beginning researchers. Sótt af http://www.google.is/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CC4QFjAA&url=http%3A%2F%2Fpsychoarshad.com%2Ffa%2Ffile-download%2F99%2FDoing-Case-Study-Research%2F&ei=fjrlUqf9N4iThgebyoGoBA&usg=AFQjCNGzyRXrd08ErDkCZV6JE5uMxxjJ_A&sig2=Xvt8twhNAfUUUgzgpOmPwCw&bvm=bv.58187178,d.ZG4
- Hannesson, G. (2012, 13. mars). Lyfjaverð. Ræða flutt á 140. löggjafarþingi – 71. fundi, Reykjavík. Sótt af <http://www.althingi.is/raeda/140/rad20120313T143927.html>

- Hannesson, G. (2013, 23. apríl). Ávarp Guðbjarts Hannessonar velferðarráðherra á ársfundi Landspítala. Sótt af <http://www.velferdarraduneyti.is/radherra/raedur-og-greinar-GH-velferdarradherra/nr/33841>
- Heilbrigðis- og tryggingamálaráðuneytið. (2007) *Lyfjastefna til 2012*. Sótt af http://www.velferdarraduneyti.is/media/Lyfjamal_-_skyrslur/Lyfjastefna_til_arsins_2012_.pdf
- Hudson, S. (2004). Hospital pharmacies. Í Mossialos, E., Mrazek, M. og Walley, T. (ritstj). *Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality* (bls. 213-226). Sótt af http://www.euro.who.int/__data/assets/pdf_file/0008/98432/E83015.pdf
- Hughes-Wilson, W., Palma, A., Schuurman, A. og Simoens, S. (2012). Paying for the orphan drug system: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? *Orphanet Journal of Rare disease*, 7(74). doi:10.1186/1750-1172-7-74
- Ingadóttir, Á. (2012, 13. mars). Lyfjaverð. Ræða flutt á 140. löggjafarþingi – 71. fundi, Reykjavík. Sótt af <http://www.athingi.is/raeda/140/rad20120313T145652.html>
- Jóhannsdóttir, Þ. J. (2009, 9. nóvember). Tilviksrannsóknir. Sótt af <http://mennta.hi.is/vefir/ust/tjona/tilviksrann.htm>
- Kanavos, P. og Vandoros S. (2010). Competition in prescription drug markets: Is parallel trade the answer? *Managerial and Decision Economics*, 31(5), 3264 - 3338.
- Kanavos, P., Sotiris V., Irwin, R., Nicod, E., Casson, M., Medical Technology Research Group - LSE Health, London School of Economics and Political Science. (2011). *Differences in costs of and access to pharmaceutical products in the EU*. Brussel: European Parliament.
- Kitzinger, J. og Barbour, R. (1999). Introduction: the challenge and promise of focus groups. Í *Developing Focus Group Research*. Kitzinger, J. og Barbour, R. (ritstj). Sage Publications: London.

Klemp, M., Frønsdal, K. B., og Facey, K. (2011). What principles should govern the use of managed entry agreements? *International Journal of Technology Assessment in Health Care*, 27(1), 77-83. doi:10.1017/S0266462310001297

Knies, S., Severens, J. L., Ament, A. J. H. A. og Evers, S. M. A. A. (2008). Using cost-effectiveness results from abroad for local policy decisions. *European Journal of Hospital Pharmacy Practice*, 14(4), 51-54. Sótt af <http://arno.unimaas.nl/show.cgi?fid=20902>

Landspítali Háskólasjúkrahús. (2013). Klínískar leiðbeiningar fyrir notkun líftæknilyfja fyrir sjúklinga með iktsýki (rheumatoid arthritis/RA) og Still's sjúkdóm hjá fullorðnum (adult Still's disease). Sótt af http://www.landspitali.is/library/Sameiginlegarskrar/Gagnasafn/BRUNNURINN/Kliniskar-leidbeiningar/S-merkt_lyf/klin_leid_ikt_ra_stills_040313.pdf

LIF. (e. d.). FAKTA 2012. *Läkemedelsmarknaden och hälso- och sjukvården. Swedish Pharmaceutical Market and Health Care*. Sótt af http://www.lif.se/Publik%20webb/Sidinnehall/Publik_Bilder/Bilder%20statis tik/FAKTA_2012_web.pdf

Lu, C., Williams, K., og Day, R. (2007). The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. *Australia and New Zealand Health Policy*, 4(1). doi:10.1186/1743-8462-4-2

Lyfjastofnun. (e. d., a). Sala lyfja með markaðsleyfi á Íslandi 2008 til 2012 [gagnagrunnur]. Sótt af <http://www.lyfjastofnun.is/Tolfraedi/>

Lyfjastofnun. (e. d., b). Lykiltölur 2011. Veltumestu lyf á Íslandi [tafla]. Sótt af <http://www.lyfjastofnun.is/Tolfraedi/Lykiltolur/>

Lyfjastofnun. (2013, ágúst). Listi yfir lyf með skilýrði eða takmarkanir sem varða öryggi og verkun við notkun lyfja. Sótt af http://www.lyfjastofnun.is/media/fraedsla_og_utgefild/Vidauki_4_nytt_skjal.pdf

Lög nr. 45/2012, um breytingu á lögum um sjúkratryggingar, nr. 112/2008, og lyfjalögum, nr. 93/1994, með síðari breytingum (greiðsluþátttaka í lyfjakostnaði).

- Lög um breytingu á lögum nr. 84/2007, um opinber innkaup.
- Medstat.dk. (2013). ATC kode [gagnagrunnur]. Sótt af <http://www.medstat.dk>
- Muurholm L., Teilmann, T. (2012). Recommendations and supporting systems. [Country focus: Denmark]. *European Journal of Hospital Pharmacy*, 19(6). doi: 10.1136/ejhp pharm-2012-000227
- Neumann, P. J. (2013). Where are we on "risk-sharing" agreements? [ritstjórnargrein]. *Value in Health*, 16(5), 701-702. doi: 10.1016/j.jval.2013.04.012
- NOMA. (2012). Ráðstefnugögn. Pharmaceutical pricing and reimbursement information network meeting, Madrid, 9.-10. febrúar 2012.
- OECD. (2012a). Expenditure on pharmaceuticals per capita and as a share of GDP, 2010 (or nearest year) [tafla]. doi: 10.1787/888932705577
- OECD. (2012b). Health expenditure per capita, total, current and capital, 2010 (or nearest year) [tafla]. doi: 10.1787/888932705425
- OECD. (2012c). *Pharmaceutical expenditure* [tafla]. doi:10.1787/pharmexp-table-2012-2-en
- OECD. (2012d). Total expenditure on health [tafla]. doi:10.1787/hlthxp-total-table-2012-2-en
- Paris, V. og Faria, R. (2010). Drawing all the benefits from pharmaceutical spending. Í *Value for money in health spending* [OECD health policy studies] (bls 155-183). doi: 10.1787/9789264088818-9-en
- Rascati, K. L. (2009). *Essentials of Pharmacoeconomics*. Philadelphia, PA: Lippincott Williams & Wilkins.
- Rascati, K. L., Drummond, M. F., Annemans, L. og Davey, P. G. (2004). Education in pharmacoeconomics: An international multidisciplinary view. *Pharmacoeconomics*, 22(3), 139-147.
- Reglugerð um lyfjagreiðslunefnd nr. 353/2013.
- Reglugerð um markaðsleyfi sérlyfja, merkingar þeirra og fylgiseðla nr. 141/2011
- Reglugerð um (2.) breytingu á reglugerð nr. 213/2005 um lyfjagreiðslunefnd nr. 380/2010, felld brott með rg. nr. 353/2013

- Ríkisendurskoðun. (2011). Þróun lyfjakostnaðar 2008 – 2010. Sótt af http://www.rikisendurskodun.is/fileadmin/media/skyrslur/throun_lyfjakostnar.pdf
- Sakshaug, S., Strøm, H., Blix, H. S., Litleskare, I., Rønning, M. og Granum, T. (2012). *Legemiddelforbruket i Norge 2007–2011. Drug Consumption in Norway 2007-2011.* Sótt af <http://www.fhi.no/dokumenter/f561247882.pdf>
- Sakshaug, S., Strøm, H., Berg, C., Blix, H. S., Litleskare, I. og Granum, T. (2013). *Legemiddelforbruket i Norge 2008–2012. Drug Consumption in Norway 2008–2012.* Sótt af http://www.legemiddelforbruk.no/download/lmfin_2013.pdf
- Schey, C., Milanova, T., og Hutchings, A. (2011). Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. *Orphanet Journal of Rare Disease*, 6(62). doi:10.1186/1750-1172-6-62
- Sjúkratryggingar Íslands. (2010). Lyfjakostnaður sjúkratrygginga 2010. Sótt af <http://www.sjukra.is/media/skyrslur/Lyfjakostnadur-Sjukratrygginga-2010.pdf>
- Sjúkratryggingar Íslands. (2011). Lyfjakostnaður sjúkratrygginga 2011. Sótt af http://www.sjukra.is/media/skyrslur/Arsskyrsla_lyf_2011.pdf
- Socialstyrelsen. (2012). *Läkemedel – statistik för år 2011.* Sótt af <http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18654/2012-3-28.pdf>
- Socialstyrelsen. (2013). *Läkemedel – statistik för år 2012.* Sótt af <http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19023/2012-3-21.pdf>
- Socialstyrelsen. (e. d.). Statistikdatabas för läkemedel [gagnagrunnur]. Sótt af <http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel>
- Sorenson, C., Drummond, M. og Kanavos, P. (2008). *Ensuring Value for Money in Health Care. The role of Health Technology Assessment in the European Union.* Sótt af http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf

- Statens serum institut. (2012). *Samlet salg af lægemidler i Danmark, 2007–2011. Total sales of medicines in Denmark, 2007–2011.* København, Statens serum institut.
- Statens serum institut. (2013). *Samlet salg af lægemidler i Danmark, 2008–2012. Total sales of medicines in Denmark, 2008–2012.* Sótt af http://www.ssi.dk/Sundhedsdataogit/Dataformidling/Laegemiddelstatistikke_r~/media/Indhold/DK%20-%20dansk/Sundhedsdata%20og%20it/NSF/Dataformidling/Laegemiddelstatistikker/5%20aars%20statistik/Samlet_salg_af_l%C3%A6gemidler_2008_2012.ashx
- Suppanz, H. (2008). *Improving cost-effectiveness in the health care sector in Iceland* [OECD Economics department working papers]. Sótt af <http://www.oecd-ilibrary.org/docserver/download/5kzbz8q042ls.pdf?expires=1385946431&id=id&accname=guest&checksum=B34BA17D64146FBFAC82EEE17E102844>
- Sveinsson, S. G. (2013a, 23. september). Nýrri lyfin keypt sjaldnar. *Morgunblaðið*, forsíða.
- Sveinsson, S. G. (2013b, 23. september). Ísland að dragast aftur úr. *Morgunblaðið*, bls 6.
- TLV. (2011). *Omrövning av TNF-hämmare* [glærur]. Sótt af <http://www.tlv.se/Upload/Genomgangen/powerpoint-omprovning-tnf-hammar-111219.pdf>
- TLV. (2012). Ráðstefnugögn. Pharmaceutical pricing and reimbursement information network meeting, Madrid, 9.-10. febrúar 2012.
- Traustadóttir, R. (e. d.) Eigindlegar aðferðir I. – Fræðilegar undirstöður og helstu einkenni [glærur]. Sótt af www.hi.is/~rannvt/ER1/1pc.ppt
- Velferðarráðuneytið. (2011a). Aukið aðhald í notkun S-merktra lyfja. Sótt af <http://www.velferdarraduneyti.is/frettir-vel/nr/32568>
- Velferðarráðuneytið. (2011b). *Skýrsla vinnuhóps um frekara aðhald í notkun S-lyfja.* Reykjavík: Velferðarráðuneytið.
- Velferðarráðuneytið. (2011c). Tillögur um kostnaðaraðhald vegna S-lyfja. Sótt af <http://www.velferdarraduneyti.is/frettir-vel/nr/32772>

Velferðarráðuneytið. (2012). *Lyfjastefna til ársins 2020 ásamt aðgerðaáætlun til ársloka 2013. Drög.* Sótt af http://www.velferdarraduneyti.is/media/frettatengt2012/Drog_ad_lyfjastefnu_til_umsagnar.pdf.

Velferðarráðuneytið. (2013). *Yfirlit útgjalda velferðarráðuneytis 2006-2013.* Reykjavík: Velferðarráðuneytið.

Vogler, S., Zimmermann, N., Leopold, C., og Joncheere, K. (2011). Pharmaceutical policies in European countries in response to the global financial crisis. *South Med Rev*, 4(2), 69-79. doi:10.5655/smr.v4i2.1004

Weinstein, M. C., Torrance, G. og McGuire, A. (2009). QALYs: The basics. *Value in health*, 12(1), S5-S9. Sótt af <http://www.ispor.org/meetings/invitational/QALY/Paper2revised.PDF>

Wettermark, B., Persson, M., Wilking, N., Kalin, M., Korkmaz, S., Hjemdahl, P. o.fl. (2010). Forecasting drug utilization and expenditure in a metropolitan health region. *BMC Health Services Research*, 10(1), 1-14. doi:10.1186/1472-6963-10-128

Vilhelmsen, A. (2012). Koordineringsrådet for ibrug-tagning af sygehusmedicin – KRIS. Sótt af <http://www.regioner.dk/sundhed/%20medicin/koordineringsr%C3%A5det+for+ibrugtagning+af+sygehusmedicin+kris>

Vilhelmsen, S. (2013, 25. febrúar). Þetta mál mun ekki stoppa hjá okkur. *Mbl.is.* Sótt af http://www.mbl.is/frettir/innlent/2013/02/25/theta_mun_ekki_stoppa_hja_okkur

World Health Organization. (2001). *How to develop and implement a national drug policy.* Geneva: World Health Organization.

World Health Organization. (2003). *Introduction in drug utilization research.* Sótt af http://www.whocc.no/filearchive/publications/drug_utilization_research.pdf

WHO Collaborating Centre for Drug Statistics Methodology. (2009, 17. desember). Definition and general considerations. Sótt af http://www.whocc.no/ddd/definition_and_general_considerations/

WHO Collaborating Centre for Drug Statistics Methodology. (2011a, 25. mars). Structure and principles. Sótt af http://www.whocc.no/atc/structure_and_principles/

WHO Collaborating Centre for Drug Statistics Methodology. (2011b, 15. febrúar). Use of ATC/DDD. Sótt af http://www.whocc.no/use_of_atc_ddd/

Þingskjal nr. 1244/2011-2012. Nefndarálit um frumvarp til laga um breytingu á lögum um sjúkratryggingar, nr. 112/2008, og lyfjalögum, nr. 93/1994, með síðari breytingum (greiðslupátttaka í lyfjakostnaði). Sótt af <http://www.althingi.is/alttext/140/s/pdf/1244.pdf>

Þórðarson, Þ. (2012, 21. júní). Flöskuháls í stjórnsýslunni tefur afgreiðslu lífsnauðsynlegra lyfja. *Vísir*. Sótt af <http://www.visir.is/floskuhals-i-stjornsyslu-tefur-afgreidslu-lifsnaudsynlegra-lyfja/article/2012120629721>

Özer, S. Thomsen, E. og Schüder, P.B. (2011). PHIS Pharma Profile – Denmark 2011. Sótt af http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/V9_DK%20PHIS%20Pharma%20Profile_final.pdf